INT97139

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.70
First Reported 2001
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 43
Total Number 45
Disease Relevance 22.05
Pain Relevance 3.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (CD83) plasma membrane (CD83)
Anatomy Link Frequency
CD86 18
dendritic cells 4
PDL-1 2
monocytes 2
blood 1
CD83 (Homo sapiens)
Pain Link Frequency Relevance Heat
chemokine 147 100.00 Very High Very High Very High
Multiple sclerosis 260 99.68 Very High Very High Very High
cytokine 161 99.50 Very High Very High Very High
Inflammation 528 95.04 Very High Very High Very High
Potency 6 94.00 High High
Chronic pancreatitis 110 91.68 High High
imagery 135 85.24 High High
cINOD 53 84.08 Quite High
rheumatoid arthritis 133 82.24 Quite High
Central nervous system 22 82.08 Quite High
Disease Link Frequency Relevance Heat
Adhesions 18 100.00 Very High Very High Very High
Cold Sores 203 99.84 Very High Very High Very High
Multiple Sclerosis 276 99.68 Very High Very High Very High
Adenocarcinoma 990 99.52 Very High Very High Very High
Cancer 1013 99.40 Very High Very High Very High
Hepatitis C Virus Infection 22 98.88 Very High Very High Very High
Breast Cancer 72 98.64 Very High Very High Very High
Skin Cancer 122 98.56 Very High Very High Very High
Phototoxic Dermatitis 144 96.36 Very High Very High Very High
Disease 160 96.20 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Dose-dependent increases in CD86 and HLA-DR (but not CD83) expression were observed at radiation doses >1 J/cm2 UVA.
Gene_expression (expression) of CD83 in CD86
1) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0.27 Pain Relevance 0
CD86, CD83 and HLA-DR surface expression of photosensitizer treated, non-irradiated as well as photosensitizer treated, irradiated cells and controls were compared (Fig. 3).
Gene_expression (expression) of CD83 in CD86
2) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0.15 Pain Relevance 0.08
CPZ, a known photosensitizer with photoallergenic and phototoxic properties, was tested with and without irradiation and the induced modulation of CD86, CD83 and HLA-DR expressions as well as cell viability were measured by flow cytometry and compared 48 h after treatment.
Gene_expression (expressions) of CD83 in CD86
3) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0 Pain Relevance 0
During these processes DCs undergo diverse phenotypical and functional changes such as reduced phagocytic ability, upregulated cell surface expression of co-stimulatory molecules and adhesion proteins, such as CD86, CD83, CD54, CD40, and MHC II antigens.
Gene_expression (expression) of CD83 in CD86 associated with adhesions
4) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0.33 Pain Relevance 0.08
The magnitude of that variability was investigated by measuring the expression of CD86, CD83 and HLA-DR on non-irradiated and irradiated, immature PBMDCs.
Gene_expression (expression) of CD83 in CD86
5) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0.12 Pain Relevance 0
The impact of irradiation on the chosen biomarkers (CD86, CD83 and HLA-DR) expression was examined.
Gene_expression (expression) of CD83 in CD86
6) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0.12 Pain Relevance 0
Minor or irrelevant modifications in CD83 expression were observed (CPZ treated, irradiated cells versus irradiated control, Fig. 3A) and only a slight increase in HLA-DR expression was induced by CPZ under irradiation (Fig. 3B).
Gene_expression (expression) of CD83
7) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0.14 Pain Relevance 0.08
Only minor modifications of HLA-DR and CD83 expressions could be detected.
Gene_expression (expressions) of CD83
8) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0 Pain Relevance 0
Moreover, the overall CD83 expression was low (2.75% without irradiation and 3.3% with irradiation) indicating the immature status of the cells and a very limited variability (Fig. 2B).
Gene_expression (expression) of CD83
9) Confidence 0.60 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0.06 Pain Relevance 0
In distinction to drug-free maturing dendritic cells, 2.5 micromol/L sulfasalazine upregulated the levels of CD14 and CD68 and downregulated the levels of CD40, CD80, and CD83 (for all CD markers, p<0.03 for difference between measurements in the absence and the presence of sulfasalazine).
Gene_expression (levels) of CD83 in dendritic cells
10) Confidence 0.55 Published 2001 Journal Croat. Med. J. Section Body Doc Link 11471196 Disease Relevance 0 Pain Relevance 0
From concentration-dependent changes in CD83 expression, we found an apparent ID50 >>1.5 micromol/L sulfasalazine.
Gene_expression (expression) of CD83
11) Confidence 0.55 Published 2001 Journal Croat. Med. J. Section Body Doc Link 11471196 Disease Relevance 0 Pain Relevance 0
On the other hand, the expression of the maturation marker CD83 was not affected under these irradiation conditions (Fig. 1B).
Gene_expression (expression) of CD83
12) Confidence 0.54 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0.12 Pain Relevance 0
To evaluate the magnitude of that variability, we investigated the basal CD86, CD83 and HLA-DR surface expression in non-irradiated and irradiated PBMDCs obtained from more than 40 different donors.
Gene_expression (expression) of CD83 in CD86
13) Confidence 0.54 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009729 Disease Relevance 0.07 Pain Relevance 0
Following a 48 h incubation, the expression of the cell surface molecules CD86, HLA-DR and CD83 was measured by flow cytometry.
Gene_expression (expression) of CD83 in CD86
14) Confidence 0.54 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC3009729 Disease Relevance 0.40 Pain Relevance 0
For example, when monocyte-derived mature DCs are administered, the expression of maturation markers like CD83, CD80, and CD86 should be measured.
Gene_expression (expression) of CD83 in CD86
15) Confidence 0.50 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727883 Disease Relevance 0.18 Pain Relevance 0.05
While CD80 expression was consistent in each culture condition, CD83 expression was much more sensitive to the differing conditions.
Gene_expression (expression) of CD83
16) Confidence 0.50 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727883 Disease Relevance 0.45 Pain Relevance 0
Of note, a partial mature blood DC phenotype, with elevated CD83 expression, correlated with the severity of breast cancer [22].
Gene_expression (expression) of CD83 in blood associated with breast cancer
17) Confidence 0.44 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.97 Pain Relevance 0.16
CD83 expression was only elevated on PDCs (median 96).
Gene_expression (expression) of CD83
18) Confidence 0.44 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.56 Pain Relevance 0.03
CD40 and CD83 expression were significantly elevated both on MDCs and PDCs in patients with PDAC, but did not reach the level seen in fully mature cells.
Gene_expression (expression) of CD83 associated with adenocarcinoma
19) Confidence 0.44 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 1.06 Pain Relevance 0.17
12 weeks after surgery, as the CD83 expression remained higher on MDCs (median 0.9%) and PDCs (median 1.5%) compared to controls (Figure 2A).
Gene_expression (expression) of CD83
20) Confidence 0.44 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.87 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox